<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">31391247</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><Issue>10</Issue><PubDate><Year>2019</Year><Month>Sep</Month><Day>03</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>An observational study on quality of life and preferences to sustain life in locked-in state.</ArticleTitle><Pagination><StartPage>e938</StartPage><EndPage>e945</EndPage><MedlinePgn>e938-e945</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000008064</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This is an observational study on well-being and end-of-life preferences in patients with amyotrophic lateral sclerosis (ALS) in the locked-in state (LIS) in a Polish sample within the EU Joint Programme-Neurodegenerative Disease Research study NEEDSinALS (NEEDSinALS.com).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this cross-sectional study, patients with ALS in LIS (n = 19) were interviewed on well-being (quality of life, depression) as a measure of psychosocial adaptation, coping mechanisms, and preferences towards life-sustaining treatments (ventilation, percutaneous endoscopic gastroscopy) and hastened death. Also, clinical data were recorded (ALS Functional Rating Scale-revised version). Standardized questionnaires (Anamnestic Comparative Self-Assessment [ACSA], Schedule for the Evaluation of Individual Quality of Life-Direct Weighting (SEIQoL-DW), ALS Depression Inventory-12 items [ADI-12], schedule of attitudes toward hastened death [SAHD], Motor Neuron Disease Coping Scale) were used, which were digitally transcribed; answers were provided via eye-tracking control. In addition, caregivers were asked to judge patients' well-being.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The majority of patients had an ACSA score &gt;0 and a SEIQoL score &gt;50% (indicating positive quality of life) and ADI-12 &lt;29 (indicating no clinically relevant depression). Physical function did not reflect subjective well-being; even more, those with no residual physical function had a positive well-being. All patients would again choose the life-sustaining techniques they currently used and their wish for hastened death was low (SAHD &lt;10). Caregivers significantly underestimated patient's well-being.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Some patients with ALS in LIS maintain a high sense of well-being despite severe physical restrictions. They are content with their life-sustaining treatments and have a strong will to live, which both may be underestimated by their families and public opinion.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kuzma-Kozakiewicz</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (M.K.-K., K.C.) and Neurodegenerative Diseases Research Group (M.K.-K.), Medical University of Warsaw, Poland; Institute of Pharmacology and Clinical Neuroscience (P.M.A.), Ume&#xe5; University, Sweden; and Department of Neurology (C.V., O.H., M.L., I.U., A.C.L., D.L.), University of Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (M.K.-K., K.C.) and Neurodegenerative Diseases Research Group (M.K.-K.), Medical University of Warsaw, Poland; Institute of Pharmacology and Clinical Neuroscience (P.M.A.), Ume&#xe5; University, Sweden; and Department of Neurology (C.V., O.H., M.L., I.U., A.C.L., D.L.), University of Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciecwierska</LastName><ForeName>Katarzyna</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (M.K.-K., K.C.) and Neurodegenerative Diseases Research Group (M.K.-K.), Medical University of Warsaw, Poland; Institute of Pharmacology and Clinical Neuroscience (P.M.A.), Ume&#xe5; University, Sweden; and Department of Neurology (C.V., O.H., M.L., I.U., A.C.L., D.L.), University of Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>V&#xe1;zquez</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (M.K.-K., K.C.) and Neurodegenerative Diseases Research Group (M.K.-K.), Medical University of Warsaw, Poland; Institute of Pharmacology and Clinical Neuroscience (P.M.A.), Ume&#xe5; University, Sweden; and Department of Neurology (C.V., O.H., M.L., I.U., A.C.L., D.L.), University of Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helczyk</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (M.K.-K., K.C.) and Neurodegenerative Diseases Research Group (M.K.-K.), Medical University of Warsaw, Poland; Institute of Pharmacology and Clinical Neuroscience (P.M.A.), Ume&#xe5; University, Sweden; and Department of Neurology (C.V., O.H., M.L., I.U., A.C.L., D.L.), University of Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loose</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (M.K.-K., K.C.) and Neurodegenerative Diseases Research Group (M.K.-K.), Medical University of Warsaw, Poland; Institute of Pharmacology and Clinical Neuroscience (P.M.A.), Ume&#xe5; University, Sweden; and Department of Neurology (C.V., O.H., M.L., I.U., A.C.L., D.L.), University of Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uttner</LastName><ForeName>Ingo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (M.K.-K., K.C.) and Neurodegenerative Diseases Research Group (M.K.-K.), Medical University of Warsaw, Poland; Institute of Pharmacology and Clinical Neuroscience (P.M.A.), Ume&#xe5; University, Sweden; and Department of Neurology (C.V., O.H., M.L., I.U., A.C.L., D.L.), University of Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (M.K.-K., K.C.) and Neurodegenerative Diseases Research Group (M.K.-K.), Medical University of Warsaw, Poland; Institute of Pharmacology and Clinical Neuroscience (P.M.A.), Ume&#xe5; University, Sweden; and Department of Neurology (C.V., O.H., M.L., I.U., A.C.L., D.L.), University of Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lul&#xe9;</LastName><ForeName>Doroth&#xe9;e</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (M.K.-K., K.C.) and Neurodegenerative Diseases Research Group (M.K.-K.), Medical University of Warsaw, Poland; Institute of Pharmacology and Clinical Neuroscience (P.M.A.), Ume&#xe5; University, Sweden; and Department of Neurology (C.V., O.H., M.L., I.U., A.C.L., D.L.), University of Ulm, Germany. dorothee.lule@uni-ulm.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Neurology. 2019 Sep 3;93(10):419-420</RefSource><PMID Version="1">31391243</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2020 Aug 11;95(6):275</RefSource><PMID Version="1">32778617</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2020 Aug 11;95(6):276</RefSource><PMID Version="1">32778618</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31391247</ArticleId><ArticleId IdType="pmc">PMC6745736</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000008064</ArticleId><ArticleId IdType="pii">WNL.0000000000008064</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Plum F, Posner JB. The Diagnosis of Stupor and Coma. Philadelphia: FA Davis; 1966.</Citation></Reference><Reference><Citation>Bourke SC, Tomlinson M, Williams TL, et al. . Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 2006;5:140&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">16426990</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory S, Siderowf A, Golaszewski AL, McCluskey L. Gastrostomy insertion in ALS patients with low vital capacity: respiratory support and survival. Neurology 2002;58:485&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">11839859</ArticleId></ArticleIdList></Reference><Reference><Citation>Lul&#xe9; D, Ehlich B, Lang D, et al. . Quality of life in fatal disease: the flawed judgement of the social environment. J Neurol 2013;260:2836&#x2013;2843.</Citation><ArticleIdList><ArticleId IdType="pubmed">23989341</ArticleId></ArticleIdList></Reference><Reference><Citation>Heritier Barras AC, Adler D, Iancu Ferfoglia R, et al. . Is tracheostomy still an option in amyotrophic lateral sclerosis? Reflections of a multidisciplinary work group. Swiss Med Wkly 2013;143:w13830.</Citation><ArticleIdList><ArticleId IdType="pubmed">23925784</ArticleId></ArticleIdList></Reference><Reference><Citation>Felgoise SH, Chakraborty BH, Bond E, et al. . Psychological morbidity in ALS: the importance of psychological assessment beyond depression alone. Amyotroph Lateral Scler 2010;11:351.</Citation><ArticleIdList><ArticleId IdType="pubmed">20235756</ArticleId></ArticleIdList></Reference><Reference><Citation>Lul&#xe9; D, H&#xe4;cker S, Ludolph A, et al. . Depression and quality of life in patients with amyotrophic lateral sclerosis. Dtsch Arztebl Int 2008;105:397&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696844</ArticleId><ArticleId IdType="pubmed">19626161</ArticleId></ArticleIdList></Reference><Reference><Citation>Lul&#xe9; D, Nonnenmacher S, Sorg S, et al. . Live and let die: existential decision processes in a fatal disease. J Neurol 2014;261:518&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">24413639</ArticleId></ArticleIdList></Reference><Reference><Citation>Roos E, Mariosa D, Ingre C, et al. . Depression in amyotrophic lateral sclerosis. Neurology 2016;86:2271&#x2013;2277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4909561</ArticleId><ArticleId IdType="pubmed">27164661</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller GA, Galanter E, Pribram KA. Plans and the Structure of Behavior. New York: Holt, Rhinehart, &amp; Winston; 1960.</Citation></Reference><Reference><Citation>Linse K, R&#xfc;ger W, Joos M, Schmitz-Peiffer H, Storch A, Hermann A. Eye-tracking-based assessment suggests preserved well-being in locked-in patients. Ann Neurol 2017;81:310&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">28074605</ArticleId></ArticleIdList></Reference><Reference><Citation>Lul&#xe9; D, Zickler C, H&#xe4;cker S, et al. . Life can be worth living in locked-in syndrome. Prog Brain Res 2009;177:339&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">19818912</ArticleId></ArticleIdList></Reference><Reference><Citation>Laureys S, Pellas F, Van Eeckhout P, et al. . The locked-in syndrome: what is it like to be conscious but paralyzed and voiceless? Prog Brain Res 2005;150:495&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">16186044</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, et al. . El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Mot Neuron Disord 2000;1:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, et al. . Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456&#x2013;2477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Hillis AE, Weintraub S, et al. . Classification of primary progressive aphasia and its variants. Neurology 2011;76:1006&#x2013;1014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. . The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function: BDNF ALS Study Group (Phase III). J Neurol Sci 1999;169:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;hm S, Aho-&#xd6;zhan HE, Keller J, et al. . Medical decisions are independent of cognitive impairment in amyotrophic lateral sclerosis. Neurology 2016;87:1737&#x2013;1738.</Citation><ArticleIdList><ArticleId IdType="pubmed">27664982</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernheim JL. How to get serious answers to the serious question: &#x201c;How have you been?&#x201d; Subjective quality of life (QOL) as an individual experiential emergent construct. Bioethics 1999;13:272&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pubmed">11657238</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Boyle C, McGee H, Hickey A, et al. . The Schedule for the Evaluation of Individual Quality of Life (SEIQoL). Administration Manual. Psychology Reports; 1993. Available at: epubs.rcsi.ie/psycholrep/39. Accessed August 4, 2008.</Citation></Reference><Reference><Citation>Hammer EM, Hacker S, Hautzinger M, et al. . Validity of the ALS Depression Inventory (ADI-12): a new screening instrument for depressive disorders in patients with amyotrophic lateral sclerosis. J Affect Disord 2008;109:213&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">18262283</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenfeld B, Breitbart W, Stein K, et al. . Measuring desire for death among the medically ill: the schedule of attitudes toward hastened death. Am J Psychiatry 1999;156:94&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">9892303</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, Kuzma-Kozakiewicz M, Keller J, et al. . Therapeutic decisions in ALS patients: cross-cultural differences and clinical implications. J Neurol 2018;265:1600&#x2013;1606.</Citation><ArticleIdList><ArticleId IdType="pubmed">29728768</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JN, Rigby SA, Burchardt F, et al. . Quality of life issues in motor neuron disease: the development and validation of a coping strategies questionnaire, the MND Coping Scale. J Neurol Sci 2001;191:79&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">11676996</ArticleId></ArticleIdList></Reference><Reference><Citation>Herschbach P. The well-being paradox in quality-of-life research: on what does our sense of well-being depend? Psychother Psych Med 2002;52:141&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">11941521</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard M, Strasser F, Gamondi C, et al. ; SMILE consortium team. Relationship between spirituality, meaning in life, psychological distress, wish for hastened death, and their influence on quality of life in palliative care patients. J Pain Symptom Manage 2017;54:514&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">28716616</ArticleId></ArticleIdList></Reference><Reference><Citation>Lul&#xe9; D, Pauli S, Altintas E, et al. . Emotional adjustment in amyotrophic lateral sclerosis (ALS). J Neurol 2012;259:334&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">21808983</ArticleId></ArticleIdList></Reference><Reference><Citation>Matuz T, Birbaumer N, Hautzinger M, K&#xfc;bler A. Coping with amyotrophic lateral sclerosis: an integrative view. J Neurol Neurosurg Psychiatry 2010;81:893&#x2013;898.</Citation><ArticleIdList><ArticleId IdType="pubmed">20587497</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayanaswami P, Bertorini TE, Pourmand R, Horner LH. Long-term tracheostomy ventilation in neuromuscular diseases: patient acceptance and quality of life. Neurorehabil Neural Repair 2000;14:135&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">15470824</ArticleId></ArticleIdList></Reference><Reference><Citation>Aho-&#xd6;zhan HE, B&#xf6;hm S, Keller J, et al. . Experience matters: neurologists' perspectives on ALS patients' well-being. J Neurol 2017;264:639&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pubmed">28120043</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke T, Galvin M, Pinto-Grau M, et al. . Caregivers of patients with amyotrophic lateral sclerosis: investigating quality of life, caregiver burden, service engagement, and patient survival. J Neurol 2017;264:898&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">28280986</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber C, Fijalkowska B, Ciecwierska K, et al. . Existential decision-making in a fatal progressive disease: how much do legal and medical frameworks matter? BMC Palliat Care 2017;16:80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5745921</ArticleId><ArticleId IdType="pubmed">29284475</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>